BillionToOne makes prenatal blood tests and liquid biopsies that count individual DNA molecules to spot genetic risks and track cancer mutations.
Revenue hit USD 0.31B in 2025 with gross margin 68.32%, up from USD 0.07B in 2023; net margin turned positive at 2.44% in 2025, driven by recurring diagnostic test sales.
Their molecular counting platform is hard to replicate, but Illumina and Guardant Health compete directly in liquid biopsy; moat_level is eroding as these rivals push similar tech.
Hold (sector percentile 34) — value C, growth A, profitability B, momentum C, revisions D-. Updated daily, sector-relative, identical for every user.
Key events, in time order
Sharp pre-market drop of 25.9% following Q2 report signals negative market reaction
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
